**Author details**

**5.** Examine the possibility of sterilizing immune protection against *P. vivax* provided by attenuated *P. falciparum* sporozoite vaccines providing an immediately highly relevant tool

*Plasmodium vivax* passes substantial challenges that may hinder achievement of global malaria elimination by 2030. The most challenging evidence is the lack of technology to detect the latent infection caused by hypnozoite. Therefore, the only tool to prevent *P. vivax* transmis-

We gratefully acknowledge Prof. Amin Soebandrio MD, PhD, Clin. Microbiol, Director of the Eijkman Institute for Molecular Biology for his encouragement and advice, and Prof. A. Asadul I. Tahir, MD, PhD, FICS, Dean of the Faculty of Medicine, Hasanuddin University for the support to DS. JKB is supported by the Vietnam Major Overseas Programme grant

sion originated from reactivation of hypnozoites is by vector control.

ACT artemisinin-based combination therapy

CHMI controlled human malaria infection

G6PD glucose-6-phosphate dehydrogenase

LLIN long-lasting insecticide treated nets

for eliminating endemic *P. vivax*.

86 Towards Malaria Elimination - A Leap Forward

**8. Conclusion**

**Acknowledgements**

from the Wellcome Trust.

CQ chloroquine

PQ primaquine

SEA Southeast Asia SR spatial repellent

CYP2D6 cytochrome P450 2D6

IRS indoor residual spraying

ITN insecticide-treated bed nets

WHO World Health Organization

**List of acronyms**

Puji BS Asih<sup>1</sup> \*, Din Syafruddin1,2 and John Kevin Baird3,4

\*Address all correspondence to: puji@eijkman.go.id

1 Eijkman Institute of Molecular Biology, Jakarta, Indonesia

2 Hasanuddin University Medical Research Centre, Makassar, Indonesia

3 Eijkman Oxford Clinical Research Unit, Jakarta, Indonesia

4 Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
